Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search
Recent Press Releases

XORTX Announces First Tranche Closing of Non-Brokered Private Placement

  • March 2, 2020December 22, 2020
  • by aaronbb

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, March 02, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed a first tranche of the non-brokered private placement announced on January 31, 2020 with the issuance of 18,259,427 units for gross proceeds of $2,556.319. 


› Read more
Recent Press Releases

XORTX Announces Re-Pricing of Private Placement

  • January 31, 2020December 22, 2020
  • by aaronbb

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Jan. 31, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease announces that it has re-priced its non-brokered private placement originally announced on April 29, 2019 to more accurately reflect the current market price of the Company’s common shares.


› Read more
Recent Press Releases

XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

  • September 19, 2019December 22, 2020
  • by aaronbb

● TMX-049 Results Show Beneficial Decrease of Urinary Albumin in T2DN ●

CALGARY, Alberta, Sept. 19, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is pleased to share, in conjunction with Teijin Pharma Limited (“Teijin”), the positive, statistically significant results from a recently completed U.S.


› Read more
Recent Press Releases

XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day

  • September 4, 2019December 22, 2020
  • by aaronbb

● New Study Shows a Novel Form of Injury Linking Uric Acid Crystals in Urine and ADPKD Progression ●

CALGARY, Alberta, Sept. 04, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight in conjunction with Polycystic Kidney Disease Awareness Day, a new, eloquent research paper that describes a previously unrecognized form of injury that can occur when uric acid or calcium oxalate crystals form in the kidneys of individuals with polycystic kidney disease. 


› Read more
Recent Press Releases

XORTX Announces Virtual Investor Conference Live Webcast

  • July 30, 2019December 22, 2020
  • by aaronbb

CALGARY, Alberta, July 30, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Dr.


› Read more
Recent Press Releases

XORTX Reports Annual & Special Meeting Results

  • July 18, 2019December 22, 2020
  • by aaronbb

CALGARY, Alberta, July 18, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s 2019 Annual and Special Meeting of Shareholders held July 17, 2019 (the “Meeting”).  


› Read more
Recent Press Releases

XORTX Shares Nature Nephrology Review

  • July 15, 2019December 22, 2020
  • by aaronbb

CALGARY, Alberta, July 15, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to recognize and highlight a recent Nature Nephrology Review article written by a global alliance of Nephrologists and thought leaders.
› Read more

Recent Press Releases

XORTX Provides Overview and Announces $5 Million Financing to Advance Clinical Trials

  • April 29, 2019December 22, 2020
  • by aaronbb

Pivotal Registration Clinical Study with XRx-008 and Phase 2b Clinical Study withTMX-049 Planned in 2020

CALGARY, Alberta, April 29, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed its audited financial statements and related management’s discussion and analysis for the year ended December 31, 2018.
› Read more

Recent Press Releases

XORTX Shares Findings of Diabetes Study in Youths Supporting High Uric Acid Advances Kidney Disease Progression

  • April 16, 2019December 22, 2020
  • by aaronbb

Adolescents with Type 2 Diabetes at Higher Risk of Kidney Disease Due to Increased Uric Acid

CALGARY, Alberta, April 16, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, congratulates the TODAY study team and Dr.


› Read more
Recent Press Releases

XORTX Shares Findings of New Diabetes Study Supporting Uric Acid as an Independent Risk Factor

  • March 25, 2019December 22, 2020
  • by aaronbb

CALGARY, Alberta, March 25, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight a recent and impactful finding by Pilemann-Lyberg et al, in the American Diabetes Association Journal – Diabetes Care on March 19, 2019.  


› Read more

Posts navigation

1 2 3 4 5

Press Releases

  • XORTX Grants Options January 12, 2021
  • XORTX Announces Private Placement January 7, 2021
  • XORTX Announces Private Placement January 7, 2021
  • XORTX Announces Grant of European Patent December 29, 2020
  • XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study November 16, 2020

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress